GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Tenofovir alafenamide (VEMLIDY)

Local RX List renal extractBase record retrieved 2026-09-07See the evidence for this drug3 sources available - open source summaries, references and comparisons

Vemlidy

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Adult HBV dialysis guidance does not supply pediatric renal doses

VEMLIDY has adult chronic-HD instructions, yet the same source explicitly lacks data for renal dose recommendations in pediatric patients. Its broader pediatric indication does not close that renal evidence gap.

Before applying: Keep adult and pediatric eligibility separate; verify HBV single-agent product versus HIV combinations, renal function and monitoring. Do not derive a pediatric dialysis schedule from the adult tablet instruction.

Also check: Adult HBV dialysis guidance does not supply pediatric renal doses

Rxlist source

GlobalRPh RX List - Vemlidy

Product / population
VEMLIDY for chronic hepatitis B; adult renal guidance, not an HIV combination-product schedule.
Renal measure
Estimated CrCl in mL/min; chronic hemodialysis.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

Adults take 25 mg once daily with food without renal adjustment at estimated CrCl >=15, or below 15 when receiving chronic hemodialysis. Give after hemodialysis on dialysis days. Below 15 without chronic hemodialysis, use is not recommended. The source explicitly lacks data to recommend doses in pediatric patients with renal impairment, despite broader age/weight indications. Assess creatinine, estimated clearance, urine glucose and protein; assess serum phosphorus in CKD. Do not transfer a fixed-dose HIV combination's renal restrictions to this single-agent HBV product.

Source revision: March 2024 | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/vemlidy-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - Vemlidy

No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.

Single-agent VEMLIDY for hepatitis B; selected adult renal guidance. Not an HIV fixed combination.

Renal method: Estimated CrCl, mL/min; Cockcroft-Gault used in the renal study.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Vemlidy

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

VEMLIDY for chronic hepatitis B; adult renal guidance, not an HIV combination-product schedule.

Renal method: Estimated CrCl in mL/min; chronic hemodialysis.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
Professional guidance

NIH HIV renal table - VEMLIDY

Adult single-agent tenofovir alafenamide for hepatitis B, not an HIV combination.

Renal method: CrCl, mL/min; chronic hemodialysis considered separately.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

population evidence gap

Adult HBV dialysis guidance does not supply pediatric renal doses

VEMLIDY has adult chronic-HD instructions, yet the same source explicitly lacks data for renal dose recommendations in pediatric patients. Its broader pediatric indication does not close that renal evidence gap.

How to use this: Keep adult and pediatric eligibility separate; verify HBV single-agent product versus HIV combinations, renal function and monitoring. Do not derive a pediatric dialysis schedule from the adult tablet instruction.

GlobalRPh RX List - Vemlidy

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - VemlidyGlobalRPh RX List - VemlidyNIH HIV renal table - VEMLIDY
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/vemlidy-drug/

Product and population scope

Single-agent VEMLIDY for hepatitis B; selected adult renal guidance. Not an HIV fixed combination.

RDM33-SCOPE-tenofovir-alafenamide-vemlidy-C1 · Source section: Exact product identity and selected populationRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Vemlidy

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Single-agent VEMLIDY for hepatitis B; selected adult renal guidance. Not an HIV fixed combination.

Renal method: Estimated CrCl, mL/min; Cockcroft-Gault used in the renal study.
Source date: Revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

No renal dosage adjustment is required at estimated CrCl of at least 15 mL/min, or below 15 in patients receiving chronic hemodialysis. On dialysis days, administer after the dialysis session. VEMLIDY is not recommended in end-stage renal disease without chronic hemodialysis. The source states that data are insufficient for renal dose recommendations in pediatric patients. Keep this single-agent guidance separate from TAF-containing fixed HIV combinations.

RDM33-rxlist-tenofovir-alafenamide-vemlidy-C1 · Source locator: Dosage in patients with renal impairment; clinical pharmacology: renal study.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/vemlidy-drug/
Retrieved
2026-09-07
Renal-function method
Estimated CrCl, mL/min; Cockcroft-Gault used in the renal study.
Source date/version
Revision date not established in selected retrieval.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
f4b3d09cb4b6f4f21471c458895df0a204ddac68f7110d35a2ce3cad9c68faf5
Rxlist

GlobalRPh RX List - Vemlidy

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · VEMLIDY for chronic hepatitis B; adult renal guidance, not an HIV combination-product schedule.

Renal method: Estimated CrCl in mL/min; chronic hemodialysis.
Source date: March 2024
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Adults take 25 mg once daily with food without renal adjustment at estimated CrCl >=15, or below 15 when receiving chronic hemodialysis. Give after hemodialysis on dialysis days. Below 15 without chronic hemodialysis, use is not recommended. The source explicitly lacks data to recommend doses in pediatric patients with renal impairment, despite broader age/weight indications. Assess creatinine, estimated clearance, urine glucose and protein; assess serum phosphorus in CKD. Do not transfer a fixed-dose HIV combination's renal restrictions to this single-agent HBV product.

RDM40-rxlist-tenofovir-alafenamide-vemlidy-36d8b8f34e-C1 · Source locator: Selected renal dosing, renal impairment, toxicity and pharmacokinetic subsections as identified in the summary.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/vemlidy-drug/
Retrieved
2026-09-07
Renal-function method
Estimated CrCl in mL/min; chronic hemodialysis.
Source date/version
March 2024
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
81da5284341fbbe61d313175686655e0c91e4b48f5001cb1dc053b5abe1de2ea
Separate professional-source layer

University and professional protocols

Professional

NIH HIV renal table - VEMLIDY

Open original reference

Open / share this exact local source

NIH ClinicalInfo HIV Guidelines · Adult single-agent tenofovir alafenamide for hepatitis B, not an HIV combination.

Renal method: CrCl, mL/min; chronic hemodialysis considered separately.
Source date: Revision date not established in selected retrieval.
Retrieved: 2026-09-07

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

VEMLIDY for hepatitis B: 25 mg orally daily. Below CrCl 15 without hemodialysis, use is not recommended. On hemodialysis, no adjustment; give after dialysis.

RDM33-professional-tenofovir-alafenamide-vemlidy-C1 · Source locator: Appendix B, named product row.

Source-specific limits

Expert-panel recommendations and FDA-label recommendations can differ. This is not a second independent trial.

Source identity and provenance
Source family
professional_guidance
Source
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-characteristics-tables-renal-hepatic-insufficiency-full
Retrieved
2026-09-07
Renal-function method
CrCl, mL/min; chronic hemodialysis considered separately.
Source date/version
Revision date not established in selected retrieval.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
189f3c5f9ac172d36298659e85701b57b52a612fdcdd4c2eb32699d7adf46401

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 2 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/vemlidy-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
278b540c79ddd60548bd1a9e4fe84282e1bdd48ab37955f8abc75184ac38931f
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report